Name
TIROFIBAN
Mode of Action
TIROFIBAN HYDROCHLORIDE IS AN ANTIPLATELET DRUG THAT REVERSIBLY INHIBITS BINDING OF FIBRINOGEN TO THE GLYCOPROTEIN IIB/IIIA RECEPTORS OF PLATELETS & INHIBITS PLATELET AGGREGATION. IT IS GIVEN WITH HEPARIN AND ASPIRIN FOR THE MANAGEMENT OF UNSTABLE ANGINA, BOTH IN PATIENTS MANAGED MEDICALLY AND IN THOSE UNDERGOING PERCUTANEOUS CORONARY PROCEDURES.
Dosage
BY INTRAVENOUS INFUSION, INITIALLY 400 NANOGRAMS/KG/MINUTE FOR 30 MINUTES, THEN 100 NANOGRAMS/KG/MINUTE FOR AT LEAST 48 HOURS (CONTINUE DURING AND FOR 12 - 24 HOURS AFTER PERCUTANEOUS CORONARY INTERVENTION); MAX. DURATION OF TREATMENT 108 HOURS
Drug Group
[ANTIPLATELET]
Cross Reaction
NONE REPORTED
Drug Interaction
Drugs Side Effect
Drug Categories
Special Precaution
Drug Safety
Monograph